

Amendments to the Claims:

1-57. (canceled)

58. (currently amended) An isolated polypeptide comprising a sequence having at least 80% amino acid sequence identity to:

(a) the amino acid sequence of the polypeptide of amino acid residues 35-273 of SEQ ID NO:506 shown in Figure 213 (SEQ ID NO:506);

(b) ~~the amino acid sequence of the polypeptide shown in Figure 213 (SEQ ID NO:506), lacking its associated signal peptide;~~

(c) ~~the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 213 (SEQ ID NO:506);~~

(d) ~~the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 213 (SEQ ID NO:506), lacking its associated signal peptide; or~~

(e) ~~the amino acid sequence of the polypeptide encoded by the full length coding sequence of the cDNA deposited under ATCC accession number 209791;~~

wherein the nucleic acid encoding the polypeptide is amplified in colon or lung tumors.

59. (currently amended) The isolated polypeptide of Claim 58 comprising a sequence having at least 85% amino acid sequence identity to:

(a) the amino acid sequence of the polypeptide of amino acid residues 35-273 of SEQ ID NO:506 shown in Figure 213 (SEQ ID NO:506);

(b) ~~the amino acid sequence of the polypeptide shown in Figure 213 (SEQ ID NO:506), lacking its associated signal peptide;~~

(c) ~~the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 213 (SEQ ID NO:506);~~

(d) ~~the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 213 (SEQ ID NO:506), lacking its associated signal peptide; or~~

(e) ~~the amino acid sequence of the polypeptide encoded by the full length coding sequence of the cDNA deposited under ATCC accession number 209791;~~

wherein the nucleic acid encoding the polypeptide is amplified in colon or lung tumors.

60. (currently amended) The isolated polypeptide of Claim 58 comprising a sequence having at least 90% amino acid sequence identity to:

(a) the amino acid sequence of the polypeptide of amino acid residues 35-273 of SEQ ID NO:506 shown in Figure 213 (SEQ ID NO:506);

(b) ~~the amino acid sequence of the polypeptide shown in Figure 213 (SEQ ID NO:506), lacking its associated signal peptide;~~

(c) ~~the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 213 (SEQ ID NO:506);~~

(d) ~~the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 213 (SEQ ID NO:506), lacking its associated signal peptide; or~~

(e) ~~the amino acid sequence of the polypeptide encoded by the full length coding sequence of the cDNA deposited under ATCC accession number 209791;~~

wherein the nucleic acid encoding the polypeptide is amplified in colon or lung tumors.

61. (currently amended) The isolated polypeptide of Claim 58 comprising a sequence having at least 95% amino acid sequence identity to:

(a) the amino acid sequence of the polypeptide of amino acid residues 35-273 SEQ ID NO:506 shown in Figure 213 (SEQ ID NO:506);

(b) ~~the amino acid sequence of the polypeptide shown in Figure 213 (SEQ ID NO:506), lacking its associated signal peptide;~~

(c) ~~the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 213 (SEQ ID NO:506);~~

(d) ~~the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 213 (SEQ ID NO:506), lacking its associated signal peptide; or~~

(e) ~~the amino acid sequence of the polypeptide encoded by the full length coding sequence of the cDNA deposited under ATCC accession number 209791;~~

wherein the nucleic acid encoding the polypeptide is amplified in colon or lung tumors.

62. (currently amended) The isolated polypeptide of Claim 58 comprising a sequence having at least 99% amino acid sequence identity to:

(a) the amino acid sequence of the polypeptide of amino acid residues 32-273 of SEQ ID NO:506 shown in Figure 213 (SEQ ID NO:506);

(b) — the amino acid sequence of the polypeptide of SEQ ID NO:506 shown in Figure 213 (SEQ ID NO:506), lacking its associated signal peptide;

(c) — the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 213 (SEQ ID NO:506);

(d) — the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 213 (SEQ ID NO:506), lacking its associated signal peptide; or

(e) — the amino acid sequence of the polypeptide encoded by the full length coding sequence of the cDNA deposited under ATCC accession number 209791;

wherein the nucleic acid encoding the polypeptide is amplified in colon or lung tumors.

63. (currently amended) An isolated polypeptide comprising:

(a) the amino acid sequence of the polypeptide of amino acid residues 35-273 of SEQ ID NO:506 shown in Figure 213 (SEQ ID NO:506);

(b) — the amino acid sequence of the polypeptide of SEQ ID NO:506 shown in Figure 213 (SEQ ID NO:506), lacking its associated signal peptide;

(c) — the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 213 (SEQ ID NO:506);

(d) — the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 213 (SEQ ID NO:506), lacking its associated signal peptide; or

(e) — the amino acid sequence of the polypeptide encoded by the full length coding sequence of the cDNA deposited under ATCC accession number 209791.

64. (cancelled)

65. (cancelled)

66. (canceled)
67. (canceled)
68. (cancelled)
69. (previously presented) A chimeric polypeptide comprising a polypeptide according to Claim 58 fused to a heterologous polypeptide.
70. (previously presented) The chimeric polypeptide of Claim 69 wherein said heterologous polypeptide is an epitope tag or an Fc region of an immunoglobulin.